Catalent Inc. | Income Statement

Fiscal year is July-June. All values USD Millions.
2014
2015
2016
2017
2018
Sales/Revenue
1,828
1,831
1,848
2,075
2,463
Cost of Goods Sold (COGS) incl. D&A
1,238
1,174
1,213
1,375
1,665
Gross Income
590
657
635
700
799
SG&A Expense
326
379
406
439
498
EBIT
264
278
230
261
301
Unusual Expense
20
61
9
25
34
Non Operating Income/Expense
14
14
13
11
4
Interest Expense
163
105
89
90
111
Pretax Income
67
113
145
136
152
Income Tax
50
98
34
26
68
Consolidated Net Income
18
210
111
110
84
Net Income
19
212
112
110
84
Net Income After Extraordinaries
22
212
112
110
84
Net Income Available to Common
16
212
112
110
84
EPS (Basic)
0.13
1.75
0.89
0.87
0.63
Basic Shares Outstanding
124
120
125
125
131
EPS (Diluted)
0.13
1.75
0.89
0.87
0.63
Diluted Shares Outstanding
124
121
126
127
133
EBITDA
407
419
370
408
491
Minority Interest Expense
1
2
-
-
-

About Catalent

View Profile
Address
14 Schoolhouse Road
Somerset New Jersey 08873
United States
Employees -
Website http://www.catalent.com
Updated 07/08/2019
Catalent, Inc. is a holding company, which engages in the provision of delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. It operates through the following segments: Softgel Technologies, Biologics and Specialty Drug Delivery, Oral Drug Delivery, and Clinical Supply Services. The Softgel Technologies segment focuses on the formulation, development, and manufacture of prescription and consumer health soft capsules, softgels, vegicaps and optishell capsules.